No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CRL240816P220000
- 7.30
- +1.10+17.74%
15min DelayTrading Jul 23 11:14 ET
7.30High7.30Low
7.30Open6.20Pre Close1 Volume49 Open Interest220.00Strike Price730.00Turnover40.82%IV4.28%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry7.30Extrinsic Value100Contract SizeAmericanOptions Type-0.4333Delta0.0169Gamma27.95Leverage Ratio-0.1773Theta-0.0608Rho-12.11Eff Leverage0.2259Vega
Intraday
- 5D
- Daily
News
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
Stephens Adjusts Price Target on Charles River Laboratories International to $250 From $280
Charles River (CRAI) Stock Rises 76% Year to Date: Here's How
Those Who Invested in Charles River Laboratories International (NYSE:CRL) Five Years Ago Are up 50%
Charles River Laboratories International, Inc.'s (NYSE:CRL) Intrinsic Value Is Potentially 31% Above Its Share Price
Is Charles River Associates (CRAI) Outperforming Other Business Services Stocks This Year?
Comments
The CEOs of both Wheeler Bio and Charles River express optimism about the partnership, believing that the integration of discovery CRO and CDMO workflows will speed up the path to first-in-human trials and bring new treatments to patients faster.
Press Release: Wheeler Bio Seals Agreement With Charles River to Offer Portable CMC(R) to Discovery Clients to Accelerate Their Journey to First-in-Human UseInsider's recent share sale, even below current price, suggests satisfaction with lower valuation. Despite high insider ownership, this selling hints at caution. The company also has 1 warning sign worth noting before buying shares.
EPS growth outshines the yearly share price gain of 12%, indicating market caution towards the stock. Despite sell-off, long term shareholders gained 12% annually over five years, suggesting the sell-off might be a growth opportunity.
1
Charles River Laboratories International's high P/E ratio is concerning due to its lower than expected growth. Investors seem more bullish than analysts, but current prices may not be sustainable without significant improvement.
The recent and long-term insider transactions demonstrate a positive outlook about the company. The significant insider ownership of the company also indicates well-aligned incentives between the management and shareholders. Charles River Laboratories International may potentially be a promising investment.
Read more